A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).
Published date:
05/16/2018
Excerpt:
...phase II study of pazopanib in patients…received pazo 800 mg qd. High plasma level of soluble VEGFR2 was associated with tumor response (p = 0.01)….suggest that pazo is a therapeutic option in DFSP....dermatofibrosarcoma protuberans (DFSP)...